Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival

Costanzo, Antonio; Malara, Giovanna; Pelucchi, Claudio; Fatiga, Francesco; Barbera, Giovanna; Franchi, Andrea; Galeone, Carlotta
July 2018
Dermatology (10188665);Jul2018, Vol. 234 Issue 1/2, p1
Academic Journal
journal article
Psoriasis is a complex and chronic disease, and, in most cases, therapies are required during all patients' lifetime. The efficacy and safety profiles of biological therapies are well established, but their effectiveness is still open to discussion. We performed a systematic review to summarize how the effectiveness of biological therapies for psoriasis is measured in real-world studies and to understand whether drug survival, a recent alternative outcome to clinical ones, is a recurrent and valid outcome of effectiveness. In March 2017, we searched for quantitative epidemiological data of psoriasis treatments using PubMed/Medline and EMBASE, and we included 65 publications. The retrospective study design (37%) was most frequent, followed by prospective registries (29%), prospective studies (19%), and retrospective administrative databases/claims. Drug survival was reported in over 60% of prospective registries and retrospective studies, and less frequently in prospective studies. A general consensus emerged in the definition of drug survival as the time patients remain under treatment with a specific therapy, and in its interpretation as an overall marker of treatment success and treatment adherence, as it represents simultaneously information on drug efficacy, drug safety, and patient satisfaction. In conclusion, notwithstanding some limitations, drug survival is a useful measurement of biological therapy effectiveness for psoriasis in daily practice. Its major advantage is that it can be computed also in already collected databases without any specific clinical information on psoriasis. This outcome, combined with evidence on clinical markers of effectiveness, can contribute to better understanding the performance of this expensive class of drugs.


Related Articles

  • Acitretin.  // AHFS Consumer Medication Information;May2020, p1 

    Acitretin is used to treat severe psoriasis (abnormal growth of skin cells that causes red, thickened, or scaly skin). Acitretin is in a class of medications called retinoids. The way acitretin works is not known.

  • Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. Salame, Nicole; Perez-Chada, Lourdes M.; Singh, Sanminder; Callis Duffin, Kristina; Garg, Amit; Gottlieb, Alice B.; Latella, John; Merola, Joseph F.; Armstrong, April W.; Perez-Chada, Lourdes M; Callis Duffin, Kristina; Gottlieb, Alice B; Merola, Joseph F; Armstrong, April W // Dermatology (10188665);Nov2018, Vol. 234 Issue 5/6, p157 

    Treatment satisfaction is paramount to the field of dermatology. Treatment dissatisfaction directly impacts patient outcomes and health care delivery. A critical need exists for standardized, validated treatment satisfaction measures in dermatology. Comprehensive evaluation of the performance of...

  • Tazarotene/corticosteroid proven superior Tx for plaque psoriasis. Guttman, Cheryl // Dermatology Times;Jun2001, Vol. 22 Issue 6, p13 

    Reports on the efficacy of switching treatment for plaque psoriasis from calcipotrine plus a corticosteroid to tazarotene 0.1 percent gel. Improvement of disease status; High level of patient satisfaction; Patient requirements; Drug tolerance.

  • Elicitation and Use of Patients' Preferences in the Treatment of Psoriasis: A Systematic Review. Umar, Nasir; Yamamoto, Shelby; Loerbroks, Adrian; Terris, Darcey // Acta Dermato-Venereologica;Jul2012, Vol. 92 Issue 4, p341 

    There is a growing advocacy to incorporate patients' preferences in psoriasis treatment. The aim of this study was to critically review the scientific evidence regarding the elicitation and use of patients' preferences in pso-riasis treatment. Published studies were systematically identified...

  • Biologies open new, long-term approaches to doctors; patients face economic challenges. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS44 

    Focuses on the biologic treatments for psoriasis. Analysis on the biologics that won approval for treating the disease; Information on other biologics that are still unapproved; Affirmation on the economic challenges faced by patients with the new drugs in the market.

  • Biologic modalities for psoriasis emerging at lightning speed. Schwanke, Jane // Dermatology Times;Sep2004 Supplement, Vol. 25, pS45 

    Discusses the emergence of biologic drugs for treating psoriasis. Issues related to cost and insurance coverage; Statement of Craig Leonardi, associate clinical professor of dermatology in St. Louis University, on the ability of the current systematic treatments to control the disease; Selection...

  • Offer systemic therapy as first-line defense. Rutledge, Barbara J. // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS16 

    Evaluates the efficacy of alefacept therapy as first-line defense for psoriasis. Impact of psoriasis on the quality of life of the patient; Number of people affected with the disease of the year; Treatment paradigms for psoriasis.

  • How Patients Take Malaria Treatment: A Systematic Review of the Literature on Adherence to Antimalarial Drugs. Bruxvoort, Katia; Goodman, Catherine; Kachur, S. Patrick; Schellenberg, David // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: High levels of patient adherence to antimalarial treatment are important in ensuring drug effectiveness. To achieve this goal, it is important to understand levels of patient adherence, and the range of study designs and methodological challenges involved in measuring adherence and...

  • Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease? Churton, Sarah; Brown, Liza; Shin, Thuzar; Korman, Neil // Drugs;Feb2014, Vol. 74 Issue 2, p169 

    Psoriasis is an inflammatory disease associated with multiple comorbidities and cardiovascular risk factors. Patients with psoriasis have an increased risk of cardiovascular disease (CVD) and cardiovascular death. It has been proposed that overlapping mechanisms of systemic inflammation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics